cj:my hat is off to you for the recap you just posted. Thanks. I understand theThat huge amount of time and savvy it takes. The ASCO info raises more questions for me than it answers. My literature search last night, which was admittedly cursory, indicated that in terms of responders Bavi+chemo does compare favorably to chemo alone. There are slightly better responses with chemo alone in the literature, and considerably worse with chemo alone, but on average,Bavi+chemo DID fare comparably, if not slightly better. Your findings were somewhat more positive (and impressive). Interestingly, Avastin+chemo seems to have fared worse on almost all scores. This raises the question of WHEN to use MABs (earlier!of course), and whether or not they should be used in combination with chemo. Seems that using Bavi to prime for irradiation is probably where we are going to settle in...and for disease where the immune system is still intact. These results keep Bavi in the running, IMO, but further clarification seems necessary before any of us can be "all in," and that makes it more and more likely to me that more time and money must be invested via partnership. Your thoughts?
Market Data 
Markets 
AI
